Tubulis announces Series C funding of €344M (US $401M) to initiate pivotal trials with lead ADC candidate TUB-040 November 4, 2025
Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers published in eBioMedicine November 4, 2025
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development November 4, 2025
KEYTRUDA + WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell RCC Following Nephrectomy November 4, 2025
GSK5764227 (GSK’227) received Orphan Drug Designation from EMA for the treatment of pulmonary NEC/SCLC November 4, 2025
Citius Oncology Signs US Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch November 4, 2025
DESTINY-Lung06 Ph 3 Trial of ENHERTU Initiated as 1L Therapy in Patients with HER2 Overexpressing Metastatic NonSquamous NSCLC November 4, 2025
FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
Myrio Therapeutics, University of Pennsylvania, and NYU Langone Health to develop next gen solid tumor T cell immunotherapeutics November 4, 2025
Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers November 4, 2025
First patient dosed in the SPaCE-MT trial of MT-302 with CAPOX with or without nivolumab or trastuzumab in 1L advanced gastroesophageal cancer November 4, 2025
SIOP 2025: Latest data of zurletrectinib (ICP-723) for the treatment of pediatric and adolescent patients with advanced solid tumors announced November 4, 2025
Updated results from GOBLET study of pelareorep + Tecentriq in patients with ≥2L metastatic SCAC announced November 4, 2025
WELIREG + LENVIMA Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced RCC November 4, 2025
FDA Meeting Requested to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer November 4, 2025
EC Approves KEYTRUDA as Part of Treatment Regimen for Adults with Resectable LA-HNSCC Expressing PD-L1 November 4, 2025
